Skip to main content
. 2018 May 8;11(5):754. doi: 10.3390/ma11050754

Figure 6.

Figure 6

Recent nanoparticle formulations enhancing drug delivery properties in atherosclerosis. (A) Solid lipid nanoparticles (SLN) are typically formed by lipids in various phases, however, the novel use of nucleolipids allows for added fine-tunability and stability, leading to the ability to encapsulate active principal ingredients (API) such as the platelet inhibitor prostacyclin (PGI2) and imaging modalities (MRI contrast agents). Reprinted (adapted) with permission from Oumzil, K. et al. Solid Lipid Nanoparticles for Image-Guided Therapy of Atherosclerosis. Bioconjug Chem 2016, 27, 569–575. Copyright 2016 American Chemical Society. (B) hydrophobic pockets within β-cyclodextrin (BCD) molecules allow for the encapsulation of potent drugs, such as rapamycin (RAP). The low toxicity and wide range of functionalization possibilities make BCD a promising tool for many studies. Reproduced (adapted) with permission from [56]. (C) Disulfide-linked Poly(l-lysine) (PLL) and heparin, a well-known natural anti-coagulant, form cationic nanoparticles that can adhere to red blood cells and ‘hitch a ride’ to the site of thrombus formation, releasing heparin as the particles degrade. Reproduced (adapted) with permission from [55].